The complexity of the role of IL-17 in the intestine is exemplified by aggravation of colitis after administration of anti-IL-17 antibody in clinical trials,17,18 whereas the antibody is effective in other inflammatory diseases, including psoriasis and ankylosing spondylitis.11,19,20. This evidence concerns the gene IL17A and ankylosing spondylitis.